SCHEMBL4299253

SCHEMBL4299253

COc1cc(NC(=O)c2ccc(C)cc2)ccc1C(=O)Nc1nccs1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.67
ADORA1 P30542 1/20 0.67
RAB9A P51151 6/20 0.66
NPC1 O15118 4/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
MAPT P10636 3/20 0.62
POLB P06746 2/20 0.62
MAPK1 P28482 1/20 0.61
TDP1 Q9NUW8 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C19 P33261 1/20 0.60
KCNMA1 Q12791 1/20 0.58
BRD4 O60885 1/20 0.57
AGER Q15109 2/20 0.56
KCNK3 O14649 1/20 0.53
KCNK9 Q9NPC2 1/20 0.53
TSHR P16473 1/20 0.52
HSD17B10 Q99714 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4286244 0.92 RAB9A (0.72) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL24934051 0.86 RAB9A (0.72) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4286353 0.86 ADORA2A (0.73) ADORA2ARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4290662 0.85 ADORA2A (0.69) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL3191373 0.83 ADORA2A (0.69) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4297591 0.82 GRM4 (0.69) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL3223685 0.81 RAB9A (1.00) ADORA2ARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4286248 0.81 RAB9A (0.72) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4299048 0.80 ADORA2A (0.68) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4290324 0.80 ADORA2A (0.74) ADORA2AADORA1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP claimed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP claimed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP claimed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US claimed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO claimed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885RAB9A 2380/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885RAB9A 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.